CIDP treatment: IVIg
Evidence-based neurology checklist on cidp treatment: ivig: Benefits This is usually used as second line treatment after steroids It has a similar benefit as plasma exchange (PE) It is effective in 50% of steroid non-responders Indications for first line use of IVIg: ahead of steroids Protocol…
Benefits
- This is usually used as second line treatment after steroids
- It has a similar benefit as plasma exchange (PE)
- It is effective in 50% of steroid non-responders
Indications for first line use of IVIg: ahead of steroids
Protocol
Response
Predictors of poor response
Predictors of good response
Subcutaneous immunoglobulins (SCIG)
Maintenance therapy
Treatment related fluctuations (TRFs)
IVIg withdrawal
Acronym
References
- Ripellino P, Fleetwood T, Cantello R, Comi C. Treatment of chronic inflammatory demyelinating polyneuropathy: from molecular bases to practical considerations. Autoimmune Dis 2014; 2014:201657.
- Eftimov F, Vermeulen M, van Doorn PA, et al. Long-term remission of CIDP after pulsed dexamethasone or short-term prednisone treatment. Neurology 2012; 78:1079-1084.
- van Schaik IN, Eftimov F, van Doorn PA, et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol 2010; 9:245-253.
- Kuitwaard K, Hahn AF, Vermeulen M, Venance SL, van Doorn PA. Intravenous immunoglobulin response in treatment-naïve chronic inflammatory demyelinating polyradiculoneuropathy. JNNP 2015; 86:1331-1336.
- Lehmann HC, Burke D, Kuwabara S. Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment. JNNP 2019; 90:981-987.
- And 18 more. Subscribe to see the full list
